Venus Remedies Ltd, on 1 December, announced that it had received market authorisation for multiple new products in the Philippines and Saudi Arabia.

In its regulatory filing, the company said that it had received market authorisation for its Paclitaxel 100m9/16.7rn1 and Zolendronic Acid 4 mg in the Philippines. The company has also received market authorisation for Bleomycin 15lU from Saudi Arabia.

Paclitaxel 100m9/16.7rn1 is a chemotherapeutic agent that is used in the treatment of various cancers, whereas Zolendronic Acid 4 mg is used to treat many forms of metabolic bone disease. Bleomycin 15lU is used as an anti-cancer medicine injection.

The company said, “These regulatory approvals signify a significant milestone for Venus Remedies Limited, reflecting the company’scompany’s commitment to advancing healthcare solutions and expanding its global presence. The company is dedicated to delivering high-quality pharmaceuticals that contribute to improving patient outcomes and addressing critical medical needs.”

In October, the company received market authorisation for six chemotherapy drugs from the Philippines, taking the company closer towards becoming the top oncology medicine supplier from India in Southeast Asia.